Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Multisystem flare of systemic lupus erythematosus presenting with severe warm autoimmune hemolytic anemia: A diagnostic and transfusion challenge

Omar Jano, Komlan Guedze, Muhammad Baba et al. Nov 03, 2025 pp. 6684-6684 10.1182/blood-2025-6684

Abstract Introduction: Warm autoimmune hemolytic anemia (wAIHA) is a potentially life-threatening complication of systemic lupus erythematos...

Adolescent cardiovascular-kidney-metabolic health and estrogen exposure: A cross-sex, gender-inclusive cohort analysis

Izola Ramalho, Srija Sivamurugan, Shreyashree Sarkar et al. Nov 03, 2025 pp. 2691-2691 10.1182/blood-2025-2691

Abstract While emerging evidence demonstrate the risk of cardiovascular-kidney-metabolic (CKM) syndrome in aging population, these risks rem...

Pulmonary Embolism–Attributable mortality among patients with breast cancer in the United States, 1999-2021

Candrika Khairani, Sina Rashedi, Nathan Watson et al. Nov 03, 2025 pp. 6252-6252 10.1182/blood-2025-6252

Abstract Introduction: Pulmonary embolism (PE) remains a leading preventable cause of morbidity and mortality in cancer patients. Over the l...

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

Wenjun Zhang, Xiyang Liu, Hongjia Zhu et al. Nov 03, 2025 pp. 927-927 10.1182/blood-2025-927

Abstract Background Although several CD19-targeting CAR-T cell therapies have been approved for the treatment of relapsed/refractory B-cell...

Efficacy and safety of spleen tyrosine kinase inhibitors in chronic immune thrombocytopenic purpura: A meta-analysis of randomized controlled trials

Faisal Rasheed, Abat Khan, Saba Musleh Ud Din et al. Nov 03, 2025 pp. 6589-6589 10.1182/blood-2025-6589

Abstract Background: Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by persistent low platelet counts...

Pharmacokinetic-pharmacodynamic modelling of von willebrand factor/factor VIII prophylaxis in von willebrand disease

Ron Mathôt, Robert Sidonio, Jr., Marjon Cnossen et al. Nov 03, 2025 pp. 3081-3081 10.1182/blood-2025-3081

Abstract Background: Long-term prophylaxis with a von Willebrand factor (VWF) concentrate is recommended in patients wit...

The simplified age and stage (SAS) score improves OS prediction after allogeneic stem cell transplantation

Alexander Angleitner, Markus Maulhardt, Michael Heuser et al. Nov 03, 2025 pp. 7815-7815 10.1182/blood-2025-7815

Abstract Background Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for acute leukemia and myel...

MC-MIL net: A multi-cascaded dual-stream multiple instance learning diagnostic framework for castleman disease.

Yue Liu, Xue Shi, Rui Zhang et al. Nov 03, 2025 pp. 7858-7858 10.1182/blood-2025-7858

Abstract Introduction: Castleman disease (CD) is a rare lymphoproliferative disorder with complex pathological features, leading to challeng...

A compact, anti-CD38 T-cell engager with a short half-life demonstrates superior anti-myeloma activity over traditional bispecific antibodies

Preeti Sharma, Miso Park, Mariam Murtadha et al. Nov 03, 2025 pp. 799-799 10.1182/blood-2025-799

Abstract Introduction: Daratumumab (Dara) is a highly effective monoclonal antibody targeting CD38, a receptor that is overexpressed on mult...

Clinical validation of a point-of-care device versus standard monitoring of vital signs in patients undergoing hematopoietic cell transplantation

Brenda Arnold, Joaquim Gasparini dos Santos, Leonardo Otuyama et al. Nov 03, 2025 pp. 7950-7950 10.1182/blood-2025-7950

Abstract Introduction: Alterations in vital signs often precede clinical deterioration, allowing for timely intervention. This is particular...

Optimized treatment for pediatric patients with low-risk Acute Myeloid Leukemia: A report from the Children's oncology group study AAML1831

Reena Pabari, Chana Glasser, Todd Alonzo et al. Nov 03, 2025 pp. 878-878 10.1182/blood-2025-878

Abstract Introduction: Prior comparison of low risk (LR) pediatric acute myeloid leukemia (AML) patients enrolled on Children's Oncology Gro...

Overview of treatment advances with complement inhibitors in patients with paroxysmal nocturnal hemoglobinuria

Carlos de Castro, Peter Hillmen, Peter Blandino et al. Nov 03, 2025 pp. 6731-6731 10.1182/blood-2025-6731

Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder that leads to lifelong risk for th...

Ex vivo treatment by mitapivat, an allosteric pyruvate kinase activator, reduced oxidative stress to support terminal erythropoiesis of non-transfusion dependent thalassemia patients due to β-thalassemia/hb e disease

Thidarat Suksangpleng, Kalaya Tachavanich, Vip Viprakasit Nov 03, 2025 pp. 2916-2916 10.1182/blood-2025-2916

Abstract Introduction: Ineffective erythropoiesis is one of the pathophysiological characteristics in the bone marrow of severely anemic pat...

The impact of extracorporeal membrane oxygenation on survival in critically ill adults with sickle cell acute chest syndrome: A national retrospective cohort study using inverse probability of treatment weighting

Benedict Amalraj, Mariana Marrero Castillo, Anil Ananthaneni Nov 03, 2025 pp. 414-414 10.1182/blood-2025-414

Abstract Introduction: Acute Chest Syndrome (ACS), a severe complication of Sickle Cell Disease (SCD) driven by a cascade of vaso-occlusion,...

Pre-transplant nutritional status and hospitalization risk in outpatient hematopoietic stem cell transplantation: A prospective study using the patient-generated subjective global assessment

Alexia E. Gonzalez-Lozano, Michelle Morcos, Héctor Alejandro Vaquera Alfaro et al. Nov 03, 2025 pp. 4285-4285 10.1182/blood-2025-4285

Abstract Background Hematopoietic stem cell transplantation (HSCT) is a complex process that can impair nutritional stat...

Resistance to imatinib of leukemia growth in non-marrow organs and eradication by dasatinib: Published cases and gene clues

Isabel Cunningham, Jianqi Yang, Debra Newman et al. Nov 03, 2025 pp. 5554-5554 10.1182/blood-2025-5554

Abstract Introduction Imatinib (IMAT) made possible complete marrow remissions of CML beginning in 1998. By 2001, relaps...

The safety and efficacy of belumosudil and ruxolitinib combination in ruxolitinib refractory chronic graft-versus-host disease

Yibo Wu, Lizhen Liu, Yi Chen et al. Nov 03, 2025 pp. 7761-7761 10.1182/blood-2025-7761

Abstract Background Chronic graft-versus-host disease (cGVHD) remains a leading cause of non-relapse mortality post-allogeneic hematopoietic...

Ruxolitinib combined with decitabine-intensified modified busulfan/cyclophosphamide conditioning regimen reduces relapse after allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia

Daihong Liu, Liping Dou, Weiqi Li Nov 03, 2025 pp. 5969-5969 10.1182/blood-2025-5969

Abstract Allogeneic hematopoietic stem cell transplantation is the only radical treatment for high-risk acute myeloid leukemia (AML), but th...

Results from the first clinical trial of the selective GlyT1 inhibitor bitopertin for steroid-refractory Diamond-Blackfan Anemia (NCT05828108)

David Young, Tania Machado, Bretagne Cowling et al. Nov 03, 2025 pp. 4992-4992 10.1182/blood-2025-4992

Abstract Background: Diamond-Blackfan Anemia (DBA) is an inherited macrocytic anemia. Despite an initial 80% steroid response rate, approxim...

Association of reproductive factors and exogenous hormone use with the risk of multiple myeloma in men and women

Nicole Caviness-Ashe, Bhavana Komanduri, Kevin Arnold et al. Nov 03, 2025 pp. 7549-7549 10.1182/blood-2025-7549

Abstract Background: Multiple Myeloma (MM) is a plasma cell malignancy with known risk factors that include increasing age, male sex, obesit...

ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.

Brandon Kale, Ariel Grajales-Cruz, Brandon Blue et al. Nov 03, 2025 pp. 5846-5846 10.1182/blood-2025-5846

Abstract Introduction: Next-generation sequencing (NGS)-based minimal residual disease (MRD) assessments are increasingly utilized in multip...

Thrombosis, bleeding, and progression in JAK2 V617F clonal hematopoiesis

Rathnam Venkat, Robert Redd, Gabriela Hobbs et al. Nov 03, 2025 pp. 3168-3168 10.1182/blood-2025-3168

Abstract BACKGROUND: JAK2 V617F mutations occur frequently in patients with myeloproliferative neoplasms (MPNs) and are associated with incre...

A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.

Chi-Joan How, Gabriela Hobbs, Aaron Gerds et al. Nov 03, 2025 pp. 5606-5606 10.1182/blood-2025-5606

Abstract Background: Myelofibrosis (MF) is a clonal hematopoietic stem cell (HSC) malignancycharacterized by aberrant activation of the JAK-...

Persistent hyponatremia as a distinctive feature of HHV-6B encephalitis in pediatric hematopoietic stem cell transplant recipients: A case series

Xiaolan Li, Yang Wan, Lipeng Liu et al. Nov 03, 2025 pp. 7731-7731 10.1182/blood-2025-7731

Abstract Background: Electrolyte imbalances are a common complication in the context of transplantation, generally presenting as mild and re...

TP53 activation by the natural quassinoid brusatol enhances venetoclax efficacy and overcomes resistance in myeloid leukemias

Shin-ichiro Kawaguchi, Kazuya Sato, Junko Izawa et al. Nov 03, 2025 pp. 1491-1491 10.1182/blood-2025-1491

Abstract Introduction Based on the encouraging results from the VIALE-A and VIALE-C trials, venetoclax in combination with azacitidine or cy...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page